OMV to divest stake in Gas Connect Austria to VERBUND

OMV to divest stake in Gas Connect Austria to VERBUND

Austria-based oil and gas company OMV has agreed to sell its 51% stake in Gas Connect Austria to VERBUND, an Austrian electricity company, for EUR 271 million. In addition to the consideration, VERBUND will assume the outstanding liabilities of Gas Connect Austria to OMV on the closing date in 2021. As per the terms of […]

Merck completes acquisition of Austrian vaccine developer Themis Bioscience

Merck completes acquisition of Austrian vaccine developer Themis Bioscience

Pharma giant Merck has wrapped up its previously announced acquisition of Austrian vaccine developer Themis Bioscience. The Austrian company is focused on developing vaccines and immune-modulation therapies for infectious diseases and cancer. Merck announced the deal last month in a move to gain access to Themis Bioscience’s coronavirus vaccine candidate. Read more about Merck acquisition […]

Greiner Bio-One launches new MiniCollect K2EDTA Capillary Collection Tube

Greiner Bio-One launches new MiniCollect K2EDTA Capillary Collection Tube

Austrian medical technology manufacturer Greiner Bio-One has launched the newly redesigned MiniCollect K2EDTA Capillary Collection Tube, designed for collecting, transporting and evaluating capillary blood samples. The newly redesigned tube has an integrated scoop which allows easy collection of droplets of blood after skin puncture, thus cutting down on the number of accessories needed. When the […]

Boehringer Ingelheim acquires ViraTherapeutics for €210m in strategic cancer immunotherapy expansion

Boehringer Ingelheim acquires ViraTherapeutics for €210m in strategic cancer immunotherapy expansion

German pharmaceutical powerhouse Boehringer Ingelheim has acquired Austria-based oncolytic virus developer ViraTherapeutics for €210 million, cementing its strategic pursuit of innovative, viral-based cancer immunotherapy solutions. This acquisition, rooted in a long-standing partnership established in 2016, aims to propel the development of cutting-edge oncolytic virus therapies, particularly targeting “cold” tumors that have shown resistance to traditional […]